4.7 Review

COVID-19 Pandemic and Vaccines Update on Challenges and Resolutions

Related references

Note: Only part of the references are listed.
Letter Public, Environmental & Occupational Health

The 501.V2 and B.1.1.7 variants of coronavirus disease 2019 (COVID-19): A new time-bomb in the making?

Taha Bin Arif

INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY (2022)

Letter Immunology

Neutralization of Variant Under Investigation B.1.617.1 With Sera of BBV152 Vaccinees

Pragya D. Yadav et al.

CLINICAL INFECTIOUS DISEASES (2022)

Review Immunology

Review Article Genotype and phenotype of COVID-19: Their roles in pathogenesis

Leila Mousavizadeh et al.

Summary: COVID-19 is a novel coronavirus belonging to the Betacoronavirus genus, with similarities and differences in genomic structure compared to other human Betacoronaviruses. It contains at least six open reading frames and important structural proteins are encoded near the one-third of the genome.

JOURNAL OF MICROBIOLOGY IMMUNOLOGY AND INFECTION (2021)

Article Immunology

Magnitude and Kinetics of Anti-Severe Acute Respiratory Syndrome Coronavirus 2 Antibody Responses and Their Relationship to Disease Severity

Kara L. Lynch et al.

Summary: Understanding the kinetics and magnitude of the host antibody response to SARS-CoV-2 is essential for understanding the pathogenesis of COVID-19 and identifying potential therapeutic targets. Research showed that IgM and IgG responses were significantly higher in patients with severe disease compared to those with mild disease, which may have implications for seroprevalence studies, therapeutics, and vaccine development strategies.

CLINICAL INFECTIOUS DISEASES (2021)

Article Immunology

Role of the Healthcare Surface Environment in Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Transmission and Potential Control Measures

Hajime Kanamori et al.

Summary: Studies have shown that SARS-CoV-2 can survive on healthcare environmental surfaces for hours to days, but viable virus has not been found. Although respiratory droplets are the main transmission route, contaminated healthcare environments may also contribute to virus transmission. Therefore, improving cleanliness and disinfection practices in healthcare facilities is crucial.

CLINICAL INFECTIOUS DISEASES (2021)

Review Pharmacology & Pharmacy

SARS-CoV-2 vaccines in advanced clinical trials: Where do we stand?

Saborni Chakraborty et al.

Summary: The ongoing COVID-19 pandemic has accelerated the development of investigational vaccines, with collaborative efforts leading to several SARS-CoV-2 vaccine candidates moving into Phase III trials in a short period of time. Current research focuses on vaccine platforms and targeted antigens to enhance the breadth and durability of vaccine responses against SARS-CoV-2.

ADVANCED DRUG DELIVERY REVIEWS (2021)

Article Microbiology

Complete Mapping of Mutations to the SARS-CoV-2 Spike Receptor-Binding Domain that Escape Antibody Recognition

Allison J. Greaney et al.

Summary: Antibodies targeting the SARS-CoV-2 spike receptor-binding domain (RBD) are key in neutralizing antibody responses, and a deep mutational scanning method was used to assess the impact of all amino-acid mutations in the RBD on antibody binding with 10 human monoclonal antibodies. The study identified the clustered escape mutations in different surfaces of the RBD that correspond to structurally defined antibody epitopes, showing that even antibodies targeting the same surface can have distinct escape mutations.

CELL HOST & MICROBE (2021)

Article Medicine, General & Internal

Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK

Merryn Voysey et al.

Summary: The ChAdOx1 nCoV-19 vaccine has been shown to have an acceptable safety profile and effectiveness against symptomatic COVID-19, with higher efficacy observed in the group that received a low dose followed by a standard dose.

LANCET (2021)

Review Microbiology

Pandemics Throughout History

Jocelyne Piret et al.

Summary: Throughout history, infectious diseases with pandemic potential have emerged regularly, including major events like the plague, cholera, flu, SARS, and MERS. Many of these diseases are zoonotic in nature, transmitted to humans through increased contact with animals. Understanding the mechanisms of pathogen transmission is crucial for prevention, and traditional public health measures like isolation, quarantine, and border control are still being used to combat the COVID-19 pandemic. Global surveillance programs and new technologies are essential for rapid detection and response to emerging infectious threats.

FRONTIERS IN MICROBIOLOGY (2021)

Article Public, Environmental & Occupational Health

Emergence of SARS-CoV-2 B.1.1.7 Lineage — United States, December 29, 2020–January 12, 2021

Summer E. Galloway et al.

MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT (2021)

Article Biochemistry & Molecular Biology

Multiple SARS-CoV-2 variants escape neutralization by vaccine-induced humoral immunity

Wilfredo F. Garcia-Beltran et al.

Summary: New variants of SARS-CoV-2 show high resistance to vaccine neutralization, with some able to escape vaccine responses with just a few mutations, highlighting the importance of developing broadly protective measures against variants.
Article Biochemistry & Molecular Biology

Evidence of escape of SARS-CoV-2 variant B.1.351 from natural and vaccine-induced sera

Daming Zhou et al.

Summary: The race to develop vaccines against SARS-CoV-2 variants, such as B.1.1.7, B.1.351, and P.1, is ongoing as these variants have mutations in the spike protein, potentially leading to immune escape. A structure-function analysis of B.1.351 revealed tighter ACE2 binding and widespread evasion from monoclonal antibody neutralization, particularly driven by the E484K mutation.
Article Microbiology

SARS-CoV-2 variant B.1.1.7 is susceptible to neutralizing antibodies elicited by ancestral spike vaccines

Xiaoying Shen et al.

Summary: Current COVID-19 vaccines target the ancestral SARS-CoV-2 spike, but the emerging B.1.1.7 variant with multiple spike mutations may impact some antibody therapies while posing no major concerns for vaccine efficacy or increased risk of reinfection.

CELL HOST & MICROBE (2021)

Article Microbiology

Comprehensive mapping of mutations in the SARS-CoV-2 receptor-binding domain that affect recognition by polyclonal human plasma antibodies

Allison J. Greaney et al.

Summary: The evolution of SARS-CoV-2 may impact the recognition of the virus by human antibody-mediated immunity, with mutations affecting antibody binding varying significantly among individuals and within the same individual over time. Despite this variability, mutations that greatly reduce antibody binding usually occur at specific sites in the RBD, with E484 being the most crucial. These findings can inform surveillance efforts for SARS-CoV-2 evolution in the future.

CELL HOST & MICROBE (2021)

Article Medicine, General & Internal

Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia

Denis Y. Logunov et al.

Summary: The Gam-COVID-Vac vaccine showed 91.6% efficacy against COVID-19 in the phase 3 trial, with good safety and tolerability in a large cohort of participants.

LANCET (2021)

Article Multidisciplinary Sciences

Sensitivity of SARS-CoV-2 B.1.1.7 to mRNA vaccine-elicited antibodies

Dami A. Collier et al.

Summary: The B.1.1.7 variant of SARS-CoV-2 exhibited reduced neutralization by vaccines and antibodies from recovered COVID-19 patients, with a more substantial loss seen when introducing the E484K mutation. This mutation poses a threat to the efficacy of the BNT162b2 vaccine.

NATURE (2021)

Article Multidisciplinary Sciences

Antibody resistance of SARS-CoV-2 variants B.1.351 and B.1.1.7

Pengfei Wang et al.

Summary: The COVID-19 pandemic has had global repercussions, with promising vaccines and monoclonal antibody therapies. However, newly detected variants of SARS-CoV-2 present challenges to these treatment options.

NATURE (2021)

Article Multidisciplinary Sciences

Neutralization of SARS-CoV-2 lineage B.1.1.7 pseudovirus by BNT162b2 vaccine-elicited human sera

Alexander Muik et al.

Summary: A new SARS-CoV-2 lineage B.1.1.7 has emerged in the UK, which is more transmissible and faster spreading than other strains. However, a study found that the BNT162b2 vaccine offers largely preserved protection against the B.1.1.7 lineage, despite some reduced neutralizing titers.

SCIENCE (2021)

Review Immunology

SARS-CoV-2 vaccines strategies: a comprehensive review of phase 3 candidates

Nikolaos C. Kyriakidis et al.

Summary: The new SARS-CoV-2 virus is rapidly spreading worldwide, causing the COVID-19 pandemic with more than 1.866 million deaths. Over 64 vaccine candidates are being developed globally, aiming to induce antibodies to prevent viral entry. Thirteen vaccine candidates are currently in Phase 3 clinical trials, showing promising progress towards approval for large-scale immunizations.

NPJ VACCINES (2021)

Article Biochemistry & Molecular Biology

SARS-CoV-2 variants B.1.351 and P.1 escape from neutralizing antibodies

Markus Hoffmann et al.

Summary: The emerging SARS-CoV-2 variants may exhibit resistance to existing neutralizing antibodies and treatments, which could have significant implications for pandemic containment efforts.
Article Biochemistry & Molecular Biology

Antibody evasion by the P.1 strain of SARS-CoV-2

Wanwisa Dejnirattisai et al.

Summary: Ending the SARS-CoV-2 pandemic requires global vaccination. New virus strains with mutations impact antibody responses, but some variants are less resistant than others. A monoclonal antibody can neutralize different variants and partially restore neutralization potency for other public antibodies.
Article Medicine, General & Internal

Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 variant of concern 202012/01 (B.1.1.7): an exploratory analysis of a randomised controlled trial

Katherine R. W. Emary et al.

Summary: A post-hoc analysis was conducted on the efficacy of the ChAdOx1 nCoV-19 vaccine against the B.1.1.7 variant of SARS-CoV-2 in the UK. The vaccine showed reduced neutralisation activity against the B.1.1.7 variant in vitro, but still demonstrated efficacy against the B.1.1.7 variant of the virus.

LANCET (2021)

News Item Multidisciplinary Sciences

MIXING COVID VACCINES TRIGGERS POTENT IMMUNE RESPONSE

Ewen Callaway

NATURE (2021)

Article Biochemistry & Molecular Biology

Sensitivity of infectious SARS-CoV-2 B.1.1.7 and B.1.351 variants to neutralizing antibodies

Delphine Planas et al.

Summary: The ability of convalescent sera from individuals with coronavirus disease 2019 and those vaccinated with BNT162b2 to neutralize SARS-CoV-2 variants B1.1.7 and B.1.351 decreases, but increases after two vaccine doses. The study found that the B.1.1.7 and B.1.351 variants may have acquired partial resistance to neutralizing antibodies generated by natural infection or vaccination, particularly in individuals with low antibody levels. This suggests that the B.1.351 variant may pose a greater risk of infection in immunized individuals.

NATURE MEDICINE (2021)

Article Medicine, General & Internal

Efficacy of NVX-CoV2373 Covid-19 Vaccine against the B.1.351 Variant

V. Shinde et al.

Summary: The NVX-CoV2373 vaccine showed efficacy in preventing Covid-19, with higher vaccine efficacy observed among HIV-negative participants. Most infections were caused by the B.1.351 variant.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

Article Multidisciplinary Sciences

DNA vaccine candidate encoding SARS-CoV-2 spike proteins elicited potent humoral and Th1 cell-mediated immune responses in mice

Eakachai Prompetchara et al.

Summary: The construction strategy of DNA vaccine candidates expressing full-length wild-type SARS-CoV-2 spike protein can induce high levels of specific binding IgG in mice. The full-length S antigen is more potent than the truncated spike (S1 or S2) in inducing neutralizing antibodies and robust T cell responses. This finding provides important insights for vaccine development.

PLOS ONE (2021)

Article Virology

The Impact on Infectivity and Neutralization Efficiency of SARS-CoV-2 Lineage B.1.351 Pseudovirus

Yeong Jun Kim et al.

Summary: A new variant of SARS-CoV-2 B.1.351 lineage is of global concern for its potential increase in transmissibility and resistance to neutralizing antibodies. This study found that the B.1.351 lineage variant showed significantly increased infectivity and enhanced cell-cell fusion compared to the Wuhan strains, particularly with the K417N and E484K mutations. In terms of antibody efficacy, Imdevimab was more effective in neutralizing the B.1.351 lineage pseudoviruses containing specific mutations, compared to Casirivimab.

VIRUSES-BASEL (2021)

Review Immunology

Wuhan to World: The COVID-19 Pandemic

Ashok Kumar et al.

Summary: COVID-19 is a severe acute respiratory syndrome caused by SARS-CoV-2, a novel virus that has spread globally with higher infectivity and mortality compared to its earlier relatives. Understanding potential transmission routes and rapidly developed diagnostics are crucial in managing the disease.

FRONTIERS IN CELLULAR AND INFECTION MICROBIOLOGY (2021)

Review Immunology

The COVID-19 Vaccines: Recent Development, Challenges and Prospects

Yuxin Yan et al.

Summary: Developing COVID-19 vaccines is crucial for the world to return to pre-pandemic normalcy. Thirteen vaccines have been approved, with over 90 candidates in clinical trials. Despite being in its infancy, current progress in vaccine development is promising.

VACCINES (2021)

Article Medicine, General & Internal

Effect of 2 Inactivated SARS-CoV-2 Vaccines on Symptomatic COVID-19 Infection in Adults A Randomized Clinical Trial

Nawal Al Kaabi et al.

Summary: This interim analysis of an ongoing randomized trial in the UAE and Bahrain evaluated the efficacy of two inactivated COVID-19 vaccines in preventing symptomatic cases and adverse events in healthy adults. The study found that both vaccines significantly reduced the risk of symptomatic COVID-19 compared to the control group, with efficacy rates of 72.8% and 78.1%. Serious adverse events were rare across all groups.

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2021)

Letter Biochemistry & Molecular Biology

SARS-CoV-2 variants of concern are emerging in India

Jasdeep Singh et al.

NATURE MEDICINE (2021)

Article Biochemistry & Molecular Biology

Immune responses against SARS-CoV-2 variants after heterologous and homologous ChAdOx1 nCoV-19/BNT162b2 vaccination

Joana Barros-Martins et al.

Summary: A study found that booster vaccination with BNT162b2 in healthcare professionals previously vaccinated with ChAdOx-1 nCoV-19 elicited more neutralizing antibodies and higher frequencies of virus-specific T cells. Additionally, BNT162b2 induced high titers of neutralizing antibodies against variants of concern, such as B.1.1.7, B.1.351, and P.1.

NATURE MEDICINE (2021)

Review Genetics & Heredity

COVID-19 and SARS-CoV-2 Variants: Current Challenges and Health Concern

Md. Zeyaullah et al.

Summary: The COVID-19 outbreak originated in Wuhan, China and quickly spread globally, challenging the current global health system. The virus displays high infectivity and pathogenicity, similar to common cold symptoms, with limited treatment options. Researchers are now focusing on monitoring viral variants and their impact on vaccine efficacy.

FRONTIERS IN GENETICS (2021)

Letter Infectious Diseases

SARS-CoV-2 spike E484K mutation reduces antibody neutralisation

Sonia Jangra et al.

LANCET MICROBE (2021)

Article Biochemistry & Molecular Biology

The D614G mutations in the SARS-CoV-2 spike protein: Implications for viral infectivity, disease severity and vaccine design

Danielle C. Groves et al.

Summary: The global spread of the SARS-CoV-2 pandemic has triggered extensive genetic sequencing efforts to characterize the geographical distribution and molecular evolution of the virus. The emergence of the D614G variant as the dominant form worldwide has led to discussions about its effects on virus characteristics, clinical outcomes of infection, and host immune response.

BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2021)

Review Virology

Coronavirus infections and immune responses

Geng Li et al.

JOURNAL OF MEDICAL VIROLOGY (2020)

Article Multidisciplinary Sciences

A pneumonia outbreak associated with a new coronavirus of probable bat origin

Peng Zhou et al.

NATURE (2020)

Article Biochemistry & Molecular Biology

Imbalanced Host Response to SARS-CoV-2 Drives Development of COVID-19

Daniel Blanco-Melo et al.

Article Immunology

Antibody Responses to SARS-CoV-2 in Patients With Novel Coronavirus Disease 2019

Juanjuan Zhao et al.

CLINICAL INFECTIOUS DISEASES (2020)

Review Biochemistry & Molecular Biology

The cytokine storm in COVID-19: An overview of the involvement of the chemokine/chemokine-receptor system

Francesca Coperchini et al.

CYTOKINE & GROWTH FACTOR REVIEWS (2020)

Article Critical Care Medicine

Pathological findings of COVID-19 associated with acute respiratory distress syndrome

Zhe Xu et al.

LANCET RESPIRATORY MEDICINE (2020)

Article Medicine, Research & Experimental

WITHDRAWN: Is global BCG vaccination coverage relevant to the progression of SARS-CoV-2 pandemic?

Mayda Gursel et al.

MEDICAL HYPOTHESES (2020)

Article Biochemistry & Molecular Biology

Extreme Genomic CpG Deficiency in SARS-CoV-2 and Evasion of Host Antiviral Defense

Xuhua Xia

MOLECULAR BIOLOGY AND EVOLUTION (2020)

News Item Multidisciplinary Sciences

THE RACE FOR CORONAVIRUS VACCINES

Ewen Callaway

NATURE (2020)

Review Biochemistry & Molecular Biology

SARS-CoV-2 infection: The role of cytokines in COVID-19 disease

Victor J. Costela-Ruiz et al.

CYTOKINE & GROWTH FACTOR REVIEWS (2020)

Article Biochemistry & Molecular Biology

Robust T Cell Immunity in Convalescent Individuals with Asymptomatic or Mild COVID-19

Takuya Sekine et al.

Article Mathematics, Interdisciplinary Applications

Time series prediction of COVID-19 by mutation rate analysis using recurrent neural network-based LSTM model

Refat Khan Pathan et al.

CHAOS SOLITONS & FRACTALS (2020)

Article Multidisciplinary Sciences

Phase I/II study of COVID-19 RNA vaccine BNT162b1 in adults

Mark J. Mulligan et al.

NATURE (2020)

Review Virology

SARS-CoV-2: characteristics and current advances in research

Yicheng Yang et al.

VIROLOGY JOURNAL (2020)

Article Virology

Characterization of accessory genes in coronavirus genomes

Christian Jean Michel et al.

VIROLOGY JOURNAL (2020)

Review Multidisciplinary Sciences

ACE2 mouse models: a toolbox for cardiovascular and pulmonary research

Hongpeng Jia et al.

NATURE COMMUNICATIONS (2020)

Article Pharmacology & Pharmacy

Role of proteolytic enzymes in the COVID-19 infection and promising therapeutic approaches

Magda Gioia et al.

BIOCHEMICAL PHARMACOLOGY (2020)

Review Immunology

COVID-19: Coronavirus Vaccine Development Updates

Jing Zhao et al.

FRONTIERS IN IMMUNOLOGY (2020)

Review Immunology

Genome evolution of SARS-CoV-2 and its virological characteristics

So Nakagawa et al.

INFLAMMATION AND REGENERATION (2020)

Article Multidisciplinary Sciences

SARS-CoV-2 D614G variant exhibits efficient replication ex vivo and transmission in vivo

Yixuan J. Hou et al.

SCIENCE (2020)

Review Biotechnology & Applied Microbiology

The Current Status of COVID-19 Vaccines

Kenneth Lundstrom

FRONTIERS IN GENOME EDITING (2020)

Review Immunology

Immunological considerations for COVID-19 vaccine strategies

Mangalakumari Jeyanathan et al.

NATURE REVIEWS IMMUNOLOGY (2020)

Article Immunology

T cell responses in patients with COVID-19

Zeyu Chen et al.

NATURE REVIEWS IMMUNOLOGY (2020)

Article Medicine, General & Internal

Is antibody-dependent enhancement playing a role in COVID-19 pathogenesis?

Negro Francesco

SWISS MEDICAL WEEKLY (2020)

Review Immunology

Defining trained immunity and its role in health and disease

Mihai G. Netea et al.

NATURE REVIEWS IMMUNOLOGY (2020)

Article Virology

Molecular Mechanism for Antibody-Dependent Enhancement of Coronavirus Entry

Yushun Wan et al.

JOURNAL OF VIROLOGY (2019)

Article Multidisciplinary Sciences

A self-adjuvanted nanoparticle based vaccine against infectious bronchitis virus

Jianping Li et al.

PLOS ONE (2018)

Article Multidisciplinary Sciences

Zika virus protection by a single low-dose nucleoside-modified mRNA vaccination

Norbert Pardi et al.

NATURE (2017)

Review Physiology

The mercurial nature of neutrophils: still an enigma in ARDS?

Andrew E. Williams et al.

AMERICAN JOURNAL OF PHYSIOLOGY-LUNG CELLULAR AND MOLECULAR PHYSIOLOGY (2014)

Article Biochemistry & Molecular Biology

Antibody-dependent SARS coronavirus infection is mediated by antibodies against spike proteins

Sheng-Fan Wang et al.

BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2014)

Article Immunology

Long-Lasting Effects of BCG Vaccination on Both Heterologous Th1/Th17 Responses and Innate Trained Immunity

Johanneke Kleinnijenhuis et al.

JOURNAL OF INNATE IMMUNITY (2014)

Article Multidisciplinary Sciences

Bacille Calmette-Guerin induces NOD2-dependent nonspecific protection from reinfection via epigenetic reprogramming of monocytes

Johanneke Kleinnijenhuis et al.

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2012)

Review Cell Biology

Insights into human CD8+ T-cell memory using the yellow fever and smallpox vaccines

Rafi Ahmed et al.

IMMUNOLOGY AND CELL BIOLOGY (2011)

Review Biochemistry & Molecular Biology

Coronaviruses An RNA proofreading machine regulates replication fidelity and diversity

Mark R. Denison et al.

RNA BIOLOGY (2011)

Letter Medicine, General & Internal

Disappearance of antibodies to SARS-associated coronavirus after recovery

Wu-Chun Cao et al.

NEW ENGLAND JOURNAL OF MEDICINE (2007)